Important regulatory notice. Type 2 diabetes is a serious medical condition treated through NHS care pathways with MHRA-licensed prescription medicines. No peptide sold as a research-use-only reference compound is a substitute for licensed type 2 diabetes care. This page is a literature-context overview of compound families discussed in published type 2 diabetes research. It is not personal-use guidance. If you have type 2 diabetes or suspect you have it, your GP is the appropriate first call.
Quick research summary. The published type 2 diabetes research literature spans GLP-1 receptor biology, beta-cell biology, insulin signalling pathways, pancreatic islet function and the broader metabolic-disease context. Several peptide families appear in this research record. Some are MHRA-licensed prescription medicines (tirzepatide, semaglutide, liraglutide). Others are research-use-only reference compounds and are not licensed treatments for type 2 diabetes in the UK.
Type 2 diabetes biology context
Type 2 diabetes literature spans insulin resistance biology, beta-cell glucotoxicity and lipotoxicity, the incretin axis (GLP-1 and GIP receptor pharmacology), glucagon biology, hepatic glucose output, and adipose-tissue endocrinology. Each axis has its own substantial peer-reviewed literature.
Licensed UK peptide medicines in type 2 diabetes
Several peptide-family medicines are MHRA-licensed for type 2 diabetes including tirzepatide (Mounjaro, dual GLP-1/GIP agonist), semaglutide (Ozempic, GLP-1 agonist), liraglutide (Victoza, GLP-1 agonist) and insulins. These are prescription-only medicines accessed through registered prescribers and NHS pathways. The Summary of Product Characteristics for each is on the electronic Medicines Compendium at emc.medicines.org.uk.
Compound families that appear in the published type 2 diabetes research record but are not licensed treatments
Cell-culture and animal-model research in type 2 diabetes has discussed several investigational and research-use-only peptide families, including retatrutide (currently investigational, in Phase 3 clinical development) and other dual and triple incretin agonist research compounds. These are not licensed UK treatments for type 2 diabetes and are sold to the laboratory market only.
UK regulatory position
No research-use-only peptide on this site is a licensed treatment for type 2 diabetes in the United Kingdom. The MHRA opened investigations in April 2026 into UK clinics making therapeutic claims about unregulated peptide products. Type 2 diabetes is a regulated clinical area and self-treatment of type 2 diabetes with unlicensed peptides is unsafe and outside the UK regulatory framework.
For laboratory researchers
Diabetes researchers may use peptide reference compounds in in-vitro beta-cell and animal-model studies. Quality requirements are batch-specific certificate of analysis, third-party HPLC purity data, mass-spectrometry identity confirmation, and clear research-use-only labelling.
If you have type 2 diabetes or suspect you have it
The standard NHS pathway is via your GP. Diabetes UK (diabetes.org.uk) is a useful UK resource. Licensed treatment is via a registered prescriber, not via a research-peptide retailer.
Research use only. Peptides Lab UK supplies research-use-only laboratory reference compounds with batch-specific certificates of analysis. Products are not for human or veterinary use.
